Determination of Voriconazole Levels in Saliva - Validation in Specific Subsets of Patients

Universitaire Ziekenhuizen KU Leuven11 enrolled

Overview

The purpose of this study is to investigate the intra-saliva penetration of voriconazole in different subpopulations. The goal is to develop, optimize and validate an easy, non-invasive and painless procedure for Therapeutic Drud Monitoring of voriconazole that can be used in children, ambulatory patients and in patients in whom blood drawing is difficult.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Pneumology Hematology Internal Medicine Pediatrics

Eligibility

Sex: ALLMin age: 5 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients from the adult hematology ward treated with voriconazole * pediatric patients treated with voriconazole, age 5-18 years * patients from the pneumology ward treated with voriconazole Exclusion Criteria: * Age under 5 years * Women who are pregnant or lactating * Mucositis stage 3 or 4 (WHO) * Patients which received the following drugs within 14 days before study entry: rifampicin, rifabutin, carbamazepine, phenytoin, phenobarbital, nevirapine, efavirenz and barbiturates. * Patients which received the following drugs within 24hours before study entry: quinidine, ergotamine, sirolimus, saquinavir, amprenavir, nelfinavir, ritonavir and sulphonylureas.

Locations (3)

University Hospital Brussels - Cystic Fibrosis Clinic

Brussels, Brussels Capital, Belgium

Ghent University Hospital - Cystic Fibrosis Clinic

Ghent, East Flanders, Belgium

University Hospitals Leuven

Leuven, Vlaams-Brabant, Belgium

Outcomes

Primary Outcomes

Voriconazole pharmacokinetics in saliva and plasma in different patient populations

Time frame: One day at steady state of voriconazole plasma levels

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.